This company has been acquired
Day One Biopharmaceuticals (DAWN) Panoramica del titolo
Day One Biopharmaceuticals, Inc. è un'azienda biofarmaceutica in fase commerciale che si occupa dell'identificazione, dello sviluppo e della commercializzazione di farmaci per le malattie dell'infanzia e dell'adulto con uguale intensità negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
DAWN Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Day One Biopharmaceuticals, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$21.53 |
| Massimo di 52 settimane | US$21.53 |
| Minimo di 52 settimane | US$5.64 |
| Beta | -1.75 |
| Variazione di 1 mese | 0.61% |
| Variazione a 3 mesi | 80.17% |
| Variazione di 1 anno | 178.17% |
| Variazione a 3 anni | 73.63% |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | -16.84% |
Notizie e aggiornamenti recenti
DAWN: Servier Cash Offer Will Define Deal Outcome And Future Pipeline Path
Analysts have reset their Day One Biopharmaceuticals price targets to $21.50, generally aligning with Servier's agreed $21.50 per share cash acquisition price. They are also shifting ratings to more neutral stances, as upside potential is now seen as capped by the deal terms.DAWN: Servier Cash Offer Will Frame Deal Completion And Pipeline Optionality
Analysts have reset their price targets on Day One Biopharmaceuticals to $21.50, a move of up to $3.00 from prior estimates. They are aligning their models with the agreed $21.50 per share cash acquisition by Servier and see limited scope for additional upside from standalone growth assumptions.DAWN: Servier Cash Offer Will Define Future Upside And Downside Potential
The analyst price target for Day One Biopharmaceuticals has shifted from $22.25 to $21.50, with analysts aligning their views to the agreed $21.50 per share cash acquisition price from Servier and adjusting their assumptions around revenue growth, profit margins, discount rate, and future P/E accordingly. Analyst Commentary Following the Servier agreement, Street research has largely converged around the US$21.50 cash offer, with multiple firms cutting ratings to Neutral or Hold and aligning price targets with the acquisition price.Recent updates
DAWN: Servier Cash Offer Will Define Deal Outcome And Future Pipeline Path
Analysts have reset their Day One Biopharmaceuticals price targets to $21.50, generally aligning with Servier's agreed $21.50 per share cash acquisition price. They are also shifting ratings to more neutral stances, as upside potential is now seen as capped by the deal terms.DAWN: Servier Cash Offer Will Frame Deal Completion And Pipeline Optionality
Analysts have reset their price targets on Day One Biopharmaceuticals to $21.50, a move of up to $3.00 from prior estimates. They are aligning their models with the agreed $21.50 per share cash acquisition by Servier and see limited scope for additional upside from standalone growth assumptions.DAWN: Servier Cash Offer Will Define Future Upside And Downside Potential
The analyst price target for Day One Biopharmaceuticals has shifted from $22.25 to $21.50, with analysts aligning their views to the agreed $21.50 per share cash acquisition price from Servier and adjusting their assumptions around revenue growth, profit margins, discount rate, and future P/E accordingly. Analyst Commentary Following the Servier agreement, Street research has largely converged around the US$21.50 cash offer, with multiple firms cutting ratings to Neutral or Hold and aligning price targets with the acquisition price.
DAWN: Ojemda Franchise And Mersana Integration Will Recast Future Earnings Power
Analysts nudged their price target on Day One Biopharmaceuticals up by $1 to $30, reflecting updated assumptions around revenue growth, profitability, and future P/E, now that recent Street research has incorporated both the latest quarterly results and ongoing Ojemda development plans. Analyst Commentary Bullish analysts are framing the latest price target move to $30 as part of a broader, constructive view on Day One Biopharmaceuticals, grounded in updated revenue, profitability, and P/E assumptions around the Ojemda franchise and recent quarterly results.Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
Feb 27
DAWN: Future Cash Flows From Mersana Acquisition Will Drive Upside Potential
Analysts raised their fair value estimate for Day One Biopharmaceuticals by $1 to $17.00, citing updated assumptions that combine higher revenue expectations, a higher future P/E, and a slightly higher discount rate. Analyst Commentary Recent Street research on Day One Biopharmaceuticals reflects a mix of optimism about the company’s potential and caution about execution risks and valuation.DAWN: Mersana Acquisition Will Recast Pipeline Risk Profile And Future Earnings Power
Narrative Update: Day One Biopharmaceuticals Analysts have adjusted their price target on Day One Biopharmaceuticals from US$27 to US$29, reflecting updated views on the Mersana acquisition, revised assumptions for future revenue growth and profit margins, and a higher future P/E multiple, even as some recent research has featured lower individual price targets. Analyst Commentary Recent Street research around Day One Biopharmaceuticals has centered on the acquisition of Mersana Therapeutics and how that deal reshapes the company’s pipeline, risk profile, and potential long term earnings power.Optimistic Investors Push Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Up 31% But Growth Is Lacking
Jan 21
DAWN: Mersana Acquisition And OJEMDA Durability Data Will Reshape Pipeline Risk Profile
Analysts have adjusted their price target on Day One Biopharmaceuticals from US$34.00 to US$27.00, citing updated assumptions on growth, margins and future P/E, along with support for the recently announced, higher cost acquisition of Mersana Therapeutics as a way to diversify the pipeline beyond OJEMDA. Analyst Commentary Bullish analysts are framing the Mersana deal as a sign that Day One is willing to pay up to secure assets that fit tightly with its focus on targeted oncology, even if the acquisition cost of up to US$285 million looks full on headline terms.DAWN: Mersana Deal Will Diversify ADC Platform And Support Future Upside
Analysts nudged their price target on Day One Biopharmaceuticals slightly higher to $22.25 per share, citing cautious optimism that the $285 million Mersana acquisition could diversify the pipeline beyond OJEMDA and enhance long term growth prospects despite its premium valuation. Analyst Commentary Bullish Takeaways Bullish analysts view the acquisition of Mersana as a strategic way to add a second antibody drug conjugate, Emi Le, alongside PTK7.We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth
Dec 19DAWN: Mersana Acquisition Will Diversify ADC Pipeline And Support Long Term Upside
Analysts slightly raised their price target for Day One Biopharmaceuticals to $22.25 per share, citing the strategically bold, though expensive, acquisition of Mersana Therapeutics as a catalyst for pipeline diversification beyond OJEMDA and as a potential source of long term value. Analyst Commentary Analyst reactions to the Mersana deal highlight a mix of strategic enthusiasm and execution risk, with many viewing the transaction as a meaningful but high stakes swing for Day One's long term growth profile and valuation.DAWN: Acquisition of ADC Candidate Will Broaden Pipeline and Patient Reach
Analysts have lowered their price target for Day One Biopharmaceuticals from $24.25 to $22.25. They cited uncertainty over the recent $285 million Mersana acquisition, despite noting improved profit margin and revenue projections.Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Fly 29% But Investors Aren't Buying For Growth
Nov 08Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 07Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Held Back By Insufficient Growth Even After Shares Climb 30%
Sep 06Expanded Clinical Indications And European Approvals Will Shape Future Oncology
Despite a substantially improved net profit margin and a lower future P/E ratio indicating enhanced profitability and valuation, the consensus analyst price target for Day One Biopharmaceuticals has been reduced from $26.25 to $24.00. Valuation Changes Summary of Valuation Changes for Day One Biopharmaceuticals The Consensus Analyst Price Target has fallen from $26.25 to $24.00.We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 18
FDA Approval And Ipsen Licensing Will Expand Pediatric Treatment Options
FDA approval and the launch of OJEMDA boost long-term revenue growth, addressing unmet medical needs and strong market uptake in pediatric glioma.Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer
Feb 03Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Jan 07Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically
Nov 04We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 12Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Jul 07Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19Rendimenti per gli azionisti
| DAWN | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 0.3% | -2.5% | 0.8% |
| 1Y | 178.2% | 26.8% | 27.7% |
Ritorno vs Industria: DAWN ha superato il US Biotechs che ha restituito 26.8 % nell'ultimo anno.
Rendimento vs Mercato: DAWN ha superato il mercato US che ha restituito 27.7 % nell'ultimo anno.
Volatilità dei prezzi
| DAWN volatility | |
|---|---|
| DAWN Average Weekly Movement | 21.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di DAWN è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di DAWN è aumentata da 14% a 21% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2018 | 178 | Jeremy Bender | dayonebio.com |
Day One Biopharmaceuticals, Inc. è una società biofarmaceutica in fase di sviluppo commerciale, impegnata nell'identificazione, nello sviluppo e nella commercializzazione di farmaci per malattie infantili e adulte con uguale intensità negli Stati Uniti. Il candidato principale dell'azienda è tovorafenib, un inibitore della chinasi del fibrosarcoma di tipo II, orale e a rapida accelerazione cerebrale, che è in fase di sperimentazione clinica di Fase II per i pazienti pediatrici con glioma di basso grado recidivato o refrattario; e Ipsen, un pLGG alterato dal raf di prima linea che è in fase di sperimentazione clinica di Fase III. L'azienda sta inoltre sviluppando DAY301, un ADC mirato a PTK7 composto da un nuovo anticorpo monoclonale umanizzato anti-PTK7 immunoglobulina G1 coniugato con un inibitore della topoisomerasi I attraverso un linker altamente stabile e idrofilo modificabile con valina-alanina (VA) per il trattamento di pazienti con tumori solidi avanzati; e Emi-Le, un coniugato anticorpo-farmaco che ha come bersaglio B7- H4 coniugato con un payload anti-tubulina auristatina come componente di una piattaforma proprietaria di linker-payload sviluppata da Mersana Therapeutics, che è in fase di sperimentazione clinica di Fase 1 per il trattamento del carcinoma mammario, del carcinoma ovarico, del carcinoma endometriale e del carcinoma adenoide-cistico (ACC).
Day One Biopharmaceuticals, Inc. Riepilogo dei fondamenti
| DAWN statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$2.22b |
| Utili (TTM) | -US$107.32m |
| Ricavi(TTM) | US$158.18m |
DAWN è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| DAWN Conto economico (TTM) | |
|---|---|
| Ricavi | US$158.18m |
| Costo del fatturato | US$17.21m |
| Profitto lordo | US$140.97m |
| Altre spese | US$248.29m |
| Utili | -US$107.32m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -1.04 |
| Margine lordo | 89.12% |
| Margine di profitto netto | -67.85% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato DAWN nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/04/25 08:58 |
| Prezzo dell'azione a fine giornata | 2026/04/22 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Day One Biopharmaceuticals, Inc. è coperta da 12 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Alec Stranahan | BofA Global Research |
| Naureen Quibria | Capital One Securities, Inc. |
| Andrea Newkirk | Goldman Sachs |